IL5 and chronic obstructive pulmonary disease: Therefore, COPD patients with elevated blood eosinophil counts may respond to biologics targeting eosinophils or associated pathways such as Mepolizumab (anti-IL-5), which reduces eosinophil activity, and Benralizumab (anti-IL-5 receptor) that can deplete eosinophils and basophils.